Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze BIIB Biogen Inc.. Please read: https://finlab.finance/en/setup?stock=BIIB

No install, open FinLab Studio

BIIB

Biogen Inc. Healthcare As of 2026-07-31 Updated daily after market close

steady quality, premium valuation.

1 active signal
EPS surprise beat
This page refreshes daily after the close. Add Biogen Inc. to your watchlist to track signal changes on your next visit.
Valuation 50Quality 70Growth 46Momentum 74Risk / liquidity 76

Is Biogen Inc. a buy? Fundamentals and valuation first

  • Quality is above average. Operating margin sits near the 67th percentile. TTM ROE is about 7.4%.

  • Valuation is expensive. TTM P/E is in the 75th percentile, above most peers.

  • Recent volatility is moderate. 60-day annualized volatility is near the 42th percentile. Average 20-day dollar volume is about $295.4M.

  • Signals are active now. EPS surprise beat currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

EPS surprise beat

Active · now 22.44897959183674%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

30 historical occurrences (since 2015-01-29)
Average forward return after EPS surprise beat。20-day: Win 51.9%, Sample 27, Median +1.03%, Excess -0.8%, Beat mkt rate 37%；60-day: Win 59.3%, Sample 27, Median +2.85%, Excess -1.24%, Beat mkt rate 40.7%；120-day: Win 46.2%, Sample 26, Median -2.47%, Excess -8.29%, Beat mkt rate 30.8%

120 days after: historical avg -0.95%

20-day +0.81%
60-day +3.04%
120-day -0.95%
20-day
60-day
120-day
Win
51.9%
59.3%
46.2%
Sample
27
27
26
Median
+1.03%
+2.85%
-2.47%
Excess
-0.8%
-1.24%
-8.29%
Beat mkt rate
37%
40.7%
30.8%

Over 26 occurrences, 120-day forward avg declined 0.95%, lagged the market by 8.29 pts; win rate 46.2%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 219+6.9% +4.3% 56.2% -26.7%
20-40 407+8.4% -5.6% 47.4% -13.2%
40-60 246-13% -20% 15.9% -26.2%
60-80 You are here148+18.8% +30.1% 73.6% +21%
80-100 372-25.3% -34.6% 16.4% -31.2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 21.73, placing it in the 76.1 own-history percentile, inside the 60-80 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+7%
Win rate 38.6% Excess -6.9%
132d
+6.8%
Win rate 67.5% Excess -0.8%
375d
Now
-22.1%
Win rate 12.8% Excess -28.9%
125d
60-day momentum down
+6.4%
Win rate 49.5% Excess -8.3%
299d
-0.6%
Win rate 32.7% Excess -6.4%
245d
-12%
Win rate 11.6% Excess -12.6%
336d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 125 historical days, 120-day forward avg declined 22.1%, win rate 12.8%, lagged the market by 28.9%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

15 times historically; 60-day forward avg -7.85%, win rate 23.1%, beating the market by -10.79 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

15 times historically; 60-day forward avg +0.78%, win rate 60%, beating the market by -3.18 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.